Biosynthetic Human Insulin and Insulin Analogs

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Biosynthetic human insulins and analogs have replaced animal insulins, allowing structural modifications for altered absorption and duration.
• Rapid-acting insulins approximate first-phase insulin release, but faster analogs are needed for optimal postprandial glucose control.
• Long-acting basal insulins exist, though controversy remains regarding hypoglycemia risks and glycemic variability.

Purpose of the Study:

• To review advancements in insulin analog development for diabetes management.
• To highlight the need for faster-acting insulins to better mimic physiological insulin secretion.
• To discuss current and future research directions in insulin therapy.

Main Methods:

• Literature review of biosynthetic insulin analogs.
• Analysis of pharmacokinetic and pharmacodynamic properties of various insulin formulations.
• Discussion of clinical applications and ongoing research in insulin therapy.

Main Results:

• Insulin analogs enable improved glycemic control, reduced hypoglycemia, and better reproducibility compared to animal insulins.
• Basal-bolus and insulin pump therapies benefit from rapid-acting analogs.
• Longer-acting insulins offer stable basal coverage with reduced nocturnal hypoglycemia.
• Inhalable insulin and coformulations (e.g., with GLP-1 receptor agonists) show clinical utility.
• Methods to accelerate insulin absorption are being explored.

Conclusions:

• Biosynthetic insulins have transformed diabetes care globally for both type 1 and type 2 diabetes.
• Structural and formulation modifications allow for more physiological insulin action.
• Improved glycemic control, reduced hypoglycemia, and fewer long-term complications are key benefits.